Τίτλος:
Carboplatin Plus Pemetrexed as First-line Treatment of Patients With
Malignant Pleural Mesothelioma: A Phase II Study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: Malignant pleural mesothelioma (MPM) is a rapidly
progressive tumor that is increasing in frequency worldwide. Treatment
options are limited, and response to chemotherapy is poor. The aim of
this phase 11 study was to evaluate the activity of the
carboplatin/pemetrexed combination as first-line chemotherapy in
patients with unresectable MPM. Patients and Methods: Chemotherapy-naive
patients with histologically confirmed MPM and an Eastern Cooperative
Oncology Group performance status of 0-2 were enrolled. Treatment
consisted of pemetrexed 500 mg/m(2) and carboplatin area under the
concentration-time curve of 5 mg/mL/min, both administered on day 1 of a
21-day cycle. The treatment continued until 6 cycles were completed or
until unacceptable toxicity or disease progression were observed.
Results: A total of 62 patients were enrolled. Of these patients, 18
(29%) had a confirmed partial response, whereas the disease remained
stable in 34 patients (54.9%) and progressed in 10 patients (16.1%).
The median overall survival (OS) was estimated at 14 months (95% CI,
11.8-16.2 months), and the median time to progression was 7 months (95%
Cl, 5.8-8.2 months). The difference in median OS between the epithelial
histologic subtype (16 months) and the sarcomatoid subtype (11 months)
was statistically significant. Conclusion: This study confirmed the
activity of the carboplatin/pemetrexed combination in the first-line
treatment of patients with MPM. It is a viable option, especially in
cases in which side effects are generally anticipated.
Συγγραφείς:
Katirtzoglou, Nikolaos
Gkiozos, Ioannis
Makrilia, Nektaria and
Tsaroucha, Emilia
Rapti, Aggeliki
Stratakos, Grigorios and
Fountzilas, Georgios
Syrigos, Konstantinos N.
Περιοδικό:
Clinical Lung Cancer
Εκδότης:
CIG MEDIA GROUP, LP
Λέξεις-κλειδιά:
Asbestos; Epithelioid; Expanded-access program; Sarcomatoid
DOI:
10.3816/CLC.2010.n.005
